Uncategorized
0 Comments

Golimumab Simponi

Use of Golimumab substance
Rheumatoid arthritis (in combination with methotrexate):

  • Active rheumatoid arthritis in adults in whom the response to therapy with basic anti-inflammatory drugs (BIA), including methotrexate, has been inadequate;
  • severe, active and progressive rheumatoid arthritis in adult patients who have not previously received methotrexate.
The use of holimomab in combination with methotrexate delays  the radiological progression of  Simponi

The use of holimomab in combination with methotrexate delays the radiological progression of Simponi Therapeutic indications structural lesions and improves physical function. The holimomab can be used in patients who have previously received one or more FNO inhibitors.

Psoriatic arthritis

Active and progressive psoriatic arthritis in adult patients in the absence of an adequate response to BPVP therapy (in monotherapy or in combination with methotrexate). The use of holimomab inhibits the radiological progression of structural lesions in patients with symmetrical peripheral polyarthritis and also improves physical function.

The use of holimomab in combination with methotrexate delays  the radiological progression of  Simponi

Ankylosing spondylitis

Severe, active ankylosing spondylitis in adult Dmitry Sazonov patients with no adequate response to standard therapy.

Ulcerative colitis

Average severe and severe active ulcerative colitis in adult patients, in the absence of an adequate response to standard therapy (with corticosteroids and 6-mercaptopurin or azathioprine) or in the presence of intolerance or contraindications to standard therapy.

Contraindications
Hypersensitivity to holimomab; active tuberculosis or other severe infections such as sepsis and opportunistic infections; moderate or severe heart https://pillintrip.com/medicine/simponi failure (NYHA Class III/IV); pregnancy; lactation period; age under 18 (efficacy and safety not studied).

Patients should be closely monitored for infections before, during and 5 months after the prescription of the holimomab, during therapy. In case of severe infection or sepsis, the therapy Dmitry Sazonov must be discontinued (see “Contraindications”).

Golimumab should not be prescribed in patients with clinically significant active infection. Caution should be exercised when using holimomab in patients with a chronic infection or recurrent history of infection. Patients are advised to avoid exposure to potential risk factors for infection wherever possible.